A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn's Disease Treated with Adalimumab or Infliximab.
Crohn's disease (CD) is a chronic and progressive disease in which the long-term management is important. This study sought to assess treatment persistence and dose escalation in the maintenance phase with adalimumab (ADA) or infliximab (IFX) in a Japanese real-world setting.



A retrospective analysis was conducted using the Japan Medical Data Center database. CD patients with either ADA or IFX prescriptions between January 2012 and February 2015 were included. Outcomes of interest were (1) failure in the induction phase (defined as switch or discontinuation) and (2) persistence in the maintenance phase (defined as the absence of switch or discontinuation over 12 months since maintenance initiation).



Overall, 133 patients (53 ADA; 80 IFX) were included. Of them, treatment failed in 26 patients (19.6%) in the induction phase. During the induction phase, there was a trend towards fewer treatment failures with ADA than IFX (88.7% vs. 75.0%; p = 0.051). Of those who completed induction, 64 patients (33 ADA; 31 IFX) had at least 12 months of valid insurance enrolment after the initiation of maintenance and 13 (5 ADA; 8 IFX) had either switch or discontinuation within 12 months after the initiation of maintenance. Probabilities of switch or discontinuation over 12 months after the maintenance date were 15.2% and 20.9% for ADA and IFX groups, respectively (p-log rank = 0.7764).



Japanese patients have a high primary response to anti-tumor necrosis factor therapy in the real-world setting, in line with the results of clinical trials. This initial therapeutic advantage can be lost during the maintenance phase, leading to dose escalation, treatment switch, or discontinuation. This study suggests that those events occurred in comparable proportions of patients treated with either ADA or IFX. However, these findings should be considered with caution given the retrospective nature and small size of the study.



Abbvie GK, Tokyo, Japan.
Department of Gastroenterology, Kitasato University School of Medicine, 1-15-1, Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0374, Japan.
Kaoru
K
Yokoyama
Abbvie GK, 3-5-27, Mita, Minato-ku, Tokyo, 108-6302, Japan. kiyotaka.yamazaki@abbvie.com.
Kiyotaka
K
Yamazaki
Abbvie GK, 3-5-27, Mita, Minato-ku, Tokyo, 108-6302, Japan.
Miiko
M
Katafuchi
Creativ-Ceutical, 215 rue du Faubourg Saint-Honoré, 75008, Paris, France.
Sameh
S
Ferchichi
D000068879:Adalimumab / Q000008:administration & dosage / Q000009:adverse effects; D000328:Adult; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects; D003424:Crohn Disease / Q000188:drug therapy / Q000453:epidemiology; D004359:Drug Therapy, Combination / Q000379:methods / Q000706:statistics & numerical data; D004363:Drug Utilization / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D000069285:Infliximab / Q000008:administration & dosage / Q000009:adverse effects; D007345:Insurance Claim Review; D007564:Japan / Q000453:epidemiology; D008134:Long-Term Care / Q000379:methods / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D000069285:Infliximab; D000068879:Adalimumab
Adalimumab; Anti-TNF; Crohn’s disease; Discontinuation; Dose escalation; Gastroenterology; Infliximab; Persistence; Switch
Eur J Gastroenterol Hepatol. 2015 Apr;27(4):436-41
25874518
Dig Dis Sci. 2016 Feb;61(2):589-96
26441281
Lancet. 2002 May 4;359(9317):1541-9
12047962
J Crohns Colitis. 2016 Jul;10 (7):795-804
26822611
Inflamm Bowel Dis. 2007 Sep;13(9):1093-9
17480021
Inflamm Bowel Dis. 2009 Dec;15(12):1837-43
19462426
Gastroenterology. 2006 Feb;130(2):323-33; quiz 591
16472588
Gastroenterology. 2007 Jan;132(1):52-65
17241859
Pharmacogenomics J. 2016 Jun;16(3):280-5
26076924
Gut. 2007 Sep;56(9):1232-9
17299059
J Crohns Colitis. 2012 Mar;6(2):160-73
22325170
Aliment Pharmacol Ther. 2011 May;33(9):987-95
21366636
N Engl J Med. 2010 Apr 15;362(15):1383-95
20393175
J Crohns Colitis. 2015 Oct;9(10):830-6
26116556
Aliment Pharmacol Ther. 2009 Feb 1;29(3):273-8
19006540
Inflamm Bowel Dis. 2008 Mar;14(3):353-8
18069674
Am J Gastroenterol. 2009 Dec;104(12):3042-9
19724267
Gut. 2009 Apr;58(4):492-500
18832518
J Gastroenterol. 2010 Sep;45(9):911-7
20232217
J Crohns Colitis. 2014 Nov;8(11):1407-16
24874893
J Gastroenterol. 2013 Jan;48(1):31-72
23090001
Nihon Rinsho. 2012 Feb;70 Suppl 1:39-43
23126064
Expert Opin Biol Ther. 2015;15(9):1257-62
26134250
Digestion. 2012;86 Suppl 1:11-5
23051721
Clinicoecon Outcomes Res. 2014 Sep 18;6:401-7
25258545
J Crohns Colitis. 2008 Dec;2(4):315-21
21172230
Gastroenterology. 1979 Oct;77(4 Pt 2):847-69
38176
Aliment Pharmacol Ther. 2014 Nov;40(9):1044-55
25185992
Am J Gastroenterol. 2002 Sep;97(9):2357-63
12358256
Inflamm Bowel Dis. 2012 Dec;18(12):2225-31
22359399
J Gastroenterol Hepatol. 2009 Jul;24(7):1258-64
19682195
J Crohns Colitis. 2016 May;10 (5):516-24
26802084
Gastroenterology. 2012 Jan;142(1):46-54.e42; quiz e30
22001864
J Crohns Colitis. 2016 Sep;10 (9):1033-41
26961546